Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 4
Submit an article Journal homepage
5,301
Views
18
CrossRef citations to date
0
Altmetric
Original Articles

Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study

Vikas Guptaa Princess Margaret Cancer Centre, Toronto, CanadaCorrespondence[email protected]
View further author information
,
Martin Griesshammerb Johannes Wesling Clinic, University of Bochum, Minden, GermanyView further author information
,
Bruno Martinoc Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Hematology Unit, Reggio Calabria, ItalyView further author information
,
Lynda Foltzd St Paul’s Hospital, Vancouver, CanadaView further author information
,
Renato Tavarese Universidade Federal de Goiás, Goiánia, BrazilView further author information
,
Haifa Kathrin Al-Alif University Hospital of Halle, Halle, GermanyView further author information
,
Pilar Giraldog Miguel Servet University Hospital and Centro de Investigacion Biomedica en Red de Enfermadades Raras (CIBERER), Zaragoza, SpainView further author information
,
Paola Guglielmellih Azienda Ospedaliero-Universitaria Careggi Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, ItalyView further author information
,
Elza Lomaiai Almazov National Medical Research Centre, St Petersburg, RussiaView further author information
,
Catherine Bouardj Novartis Pharma SAS, Rueil-Malmaison, FranceView further author information
,
Carole Paleyk Novartis Pharma Corp, East Hanover, NJ, USAView further author information
,
Ranjan Tiwaril Novartis Healthcare Pvt Ltd, Hyderabad, IndiaView further author information
,
Evren Zorm Novartis AG, Basel, SwitzerlandView further author information
&
Pia Raananin Rabin Medical Center, Petah Tikva & Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, IsraelView further author information
 show all
Pages 918-926 | Received 04 Aug 2020, Accepted 26 Oct 2020, Published online: 19 Nov 2020

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Keita Kirito. (2023) Recent progress of JAK inhibitors for hematological disorders. Immunological Medicine 46:3, pages 131-142.
Read now
Naveen Pemmaraju, Prithviraj Bose, Raajit Rampal, Aaron T. Gerds, Angela Fleischman & Srdan Verstovsek. (2023) Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leukemia & Lymphoma 64:6, pages 1063-1081.
Read now
Timothy Devos, Dominik Selleslag, Nikki Granacher, Violaine Havelange & Fleur Samantha Benghiat. (2022) Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Hematology 27:1, pages 23-31.
Read now
James T. England & Vikas Gupta. (2022) Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis. Expert Opinion on Pharmacotherapy 23:15, pages 1677-1686.
Read now
Douglas Tremblay & Ronald Hoffman. (2021) Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials. Expert Opinion on Emerging Drugs 26:4, pages 351-362.
Read now

Articles from other publishers (13)

Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Naval G. Daver, Koji Sasaki, Helen T. Chifotides, Lingsha Zhou, Hagop M. Kantarjian, Zeev Estrov & Srdan Verstovsek. (2023) The role of therapy in the outcome of patients with myelofibrosis. Cancer 129:18, pages 2828-2835.
Crossref
Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Lingsha Zhou, Sherry Pierce, Zeev Estrov, Hagop Kantarjian & Srdan Verstovsek. (2023) Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematologica, pages 1-8.
Crossref
Srdan Verstovsek, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Ruben A. Mesa, Peg Squier, J. E. Hamer‐Maansson & Claire Harrison. (2023) Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies. Cancer 129:11, pages 1681-1690.
Crossref
Francesca Palandri, Haifa Kathrin Al-Ali, Paola Guglielmelli, Mike W. Zuurman, Rajendra Sarkar & Vikas Gupta. (2023) Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study. Cancers 15:10, pages 2859.
Crossref
Srdan Verstovsek. (2023) How I manage anemia related to myelofibrosis and its treatment regimens. Annals of Hematology 102:4, pages 689-698.
Crossref
Joanna Góra-Tybor, Aleksandra Gołos, Damian Mikulski, Grzegorz Helbig, Tomasz Sacha, Krzysztof Lewandowski, Joanna Niesiobędzka-Krężel, Maria Bieniaszewska, Hubert Wysogląd, Olga Grzybowska-Izydorczyk, Ilona Seferyńska, Marta Sobas, Maria Czyżewska, Agnieszka Michalska, Waldemar Sawicki, Malwina Mazur, Marek Hus, Ewa Bodzenta, Magdalena Olszewska-Szopa, Martyna Włodarczyk, Elżbieta Patkowska, Wojciech Świstek & Krzysztof Jamroziak. (2022) Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry. Clinical Lymphoma Myeloma and Leukemia.
Crossref
Aaron T. GerdsJason GotlibHaris AliPrithviraj BoseAndrew DunbarAmro ElshouryTracy I. GeorgeKrishna GundaboluElizabeth HexnerGabriela S. HobbsTania JainCatriona JamiesonPaul R. KaesbergAndrew T. KuykendallYazan MadanatBrandon McMahonSanjay R. MohanKalyan V. NadimintiStephen OhAnimesh PardananiNikolai PodoltsevLindsay ReinRachel SalitBrady L. SteinMoshe TalpazPankit VachhaniMartha WadleighSarah WallDawn C. Ward, Mary Anne BergmanCindy Hochstetler. (2022) Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 20:9, pages 1033-1062.
Crossref
John O. Mascarenhas & Srdan Verstovsek. (2022) The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes. Cancer 128:14, pages 2717-2727.
Crossref
Francesco Passamonti, Florian H Heidel, Rohan C Parikh, Mayank Ajmera, Derek Tang, Jose Alberto Nadal, Keith L Davis & Pranav Abraham. (2022) Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review. Future Oncology 18:18, pages 2217-2231.
Crossref
Margherita Maffioli, Barbara MoraSomedeb Ball, Alessandra Iurlo, Elena Maria ElliMaria Chiara FinazziNicola PolverelliElisa Rumi, Marianna CaramellaMaria Cristina CarraroMariella D’AddaAlfredo Molteni, Cinzia SissaFrancesca LunghiAlessandro VismaraMarta Ubezio, Anna GuidettiSabrina CaberlonMichela AnghilieriRami Komrokji, Daniele Cattaneo, Matteo Giovanni Della Porta, Toni Giorgino, Lorenza Bertù, Marco BrocinerAndrew Kuykendall & Francesco Passamonti. (2022) A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Advances 6:6, pages 1855-1864.
Crossref
Dawn Maze. (2022) Myeloproliferative neoplasms in 2022. Canadian Hematology Today.
Crossref
James England & Vikas Gupta. (2021) Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?. Hematology 2021:1, pages 453-462.
Crossref
Francisco Cervantes, David M. Ross, Atanas Radinoff, Francesca Palandri, Alexandr Myasnikov, Alessandro M. Vannucchi, Pierre Zachee, Heinz Gisslinger, Norio Komatsu, Lynda Foltz, Francesco Mannelli, Francesco Passamonti, Geralyn Gilotti, Islam Sadek, Ranjan Tiwari, Evren Zor & Haifa Kathrin Al-Ali. (2021) Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia 35:12, pages 3455-3465.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.